Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.24 USD | -1.82% | -6.61% | +25.95% |
Financials (USD)
Sales 2024 * | 153M | Sales 2025 * | 428M | Capitalization | 2.87B |
---|---|---|---|---|---|
Net income 2024 * | -356M | Net income 2025 * | -199M | EV / Sales 2024 * | 18.3 x |
Net cash position 2024 * | 72.44M | Net cash position 2025 * | 144M | EV / Sales 2025 * | 6.36 x |
P/E ratio 2024 * |
-7.85
x | P/E ratio 2025 * |
-15
x | Employees | 557 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.57% |
Latest transcript on Iovance Biotherapeutics, Inc.
1 day | -1.82% | ||
1 week | -6.61% | ||
Current month | -13.07% | ||
1 month | -12.63% | ||
3 months | +11.91% | ||
6 months | +102.77% | ||
Current year | +25.95% |
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - | |
0.93% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.11% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 10.24 | -1.82% | 4,505,696 |
24-05-16 | 10.43 | -2.34% | 4,705,810 |
24-05-15 | 10.68 | -0.37% | 7,036,122 |
24-05-14 | 10.72 | -1.47% | 6,560,833 |
24-05-13 | 10.88 | -0.78% | 9,969,784 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.95% | 2.87B | |
-31.90% | 9.3B | |
-6.25% | 3.1B | |
-13.96% | 2.17B | |
-16.83% | 1.75B | |
+72.82% | 1.5B | |
+29.17% | 807M | |
-2.62% | 759M | |
-26.33% | 532M | |
+4.97% | 313M |
- Stock Market
- Equities
- IOVA Stock